Feds stop sending Eli Lilly’s COVID-19 cocktail to Illinois on concerns of P.1 variant

Eli Lilly's COVID-19 antibody bamlanivimab already lost its solo FDA authorization as viral variants cropped up. Now, the company's two-antibody combo is running into trouble.

Federal officials are pausing shipments of the bamlanivimab-etesevimab cocktail to Illinois because of worries about one specific variant called P.1.